These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 24385214)

  • 1. Unbiased compound screening identifies unexpected drug sensitivities and novel treatment options for gastrointestinal stromal tumors.
    Boichuk S; Lee DJ; Mehalek KR; Makielski KR; Wozniak A; Seneviratne DS; Korzeniewski N; Cuevas R; Parry JA; Brown MF; Zewe J; Taguchi T; Kuan SF; Schöffski P; Debiec-Rychter M; Duensing A
    Cancer Res; 2014 Feb; 74(4):1200-13. PubMed ID: 24385214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug repurposing identifies therapeutic agents for gastrointestinal stromal tumors.
    Thorne J
    Future Med Chem; 2014 Apr; 6(6):602. PubMed ID: 25028758
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhibition of fibroblast growth factor receptor-signaling sensitizes imatinib-resistant gastrointestinal stromal tumors to low doses of topoisomerase II inhibitors.
    Boichuk S; Dunaev P; Galembikova A; Mustafin I; Valeeva E
    Anticancer Drugs; 2018 Jul; 29(6):549-559. PubMed ID: 29697413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
    Demetri GD
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Medical treatment for gastrointestinal stromal tumor (GIST) in Japan].
    Sato A; Hamada K; Imataka H
    Gan To Kagaku Ryoho; 2012 May; 39(5):708-12. PubMed ID: 22584320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)].
    Miyake M; Takeda Y; Hasuike Y; Kashiwazaki M; Mishima H; Ikenaga M; Mano M; Takada Y; Hirota S; Tsujinaka T
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1791-4. PubMed ID: 15553717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathology of gastrointestinal stromal tumors.
    Hirota S; Isozaki K
    Pathol Int; 2006 Jan; 56(1):1-9. PubMed ID: 16398673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of FGFR2-Signaling Attenuates a Homology-Mediated DNA Repair in GIST and Sensitizes Them to DNA-Topoisomerase II Inhibitors.
    Sergei B; Pavel D; Aigul G; Firyuza B; Ilmira N; Ilshat M; Aida A; Refat K; Natalia A; Elena S; Vera G
    Int J Mol Sci; 2020 Jan; 21(1):. PubMed ID: 31948066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
    Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
    Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapies of gastrointestinal stromal tumors (GIST)--the next frontiers.
    Duensing S; Duensing A
    Biochem Pharmacol; 2010 Sep; 80(5):575-83. PubMed ID: 20385106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Small-molecule inhibitors against KIT and PDGFRs especially in GISTs].
    Shiba K; Matsumoto T; Hirota S
    Gan To Kagaku Ryoho; 2009 Jul; 36(7):1080-5. PubMed ID: 19620796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ethyl-2-amino-pyrrole-3-carboxylates are active against imatinib-resistant gastrointestinal stromal tumors in vitro and in vivo.
    Boichuk S; Galembikova A; Dunaev P; Micheeva E; Novikova M; Khromova N; Kopnin P
    Anticancer Drugs; 2019 Jun; 30(5):475-484. PubMed ID: 30986804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib mesylate induces quiescence in gastrointestinal stromal tumor cells through the CDH1-SKP2-p27Kip1 signaling axis.
    Liu Y; Perdreau SA; Chatterjee P; Wang L; Kuan SF; Duensing A
    Cancer Res; 2008 Nov; 68(21):9015-23. PubMed ID: 18974147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High efficacy of panobinostat towards human gastrointestinal stromal tumors in a xenograft mouse model.
    Floris G; Debiec-Rychter M; Sciot R; Stefan C; Fieuws S; Machiels K; Atadja P; Wozniak A; Faa G; Schöffski P
    Clin Cancer Res; 2009 Jun; 15(12):4066-76. PubMed ID: 19509176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells.
    Sambol EB; Ambrosini G; Geha RC; Kennealey PT; Decarolis P; O'connor R; Wu YV; Motwani M; Chen JH; Schwartz GK; Singer S
    Cancer Res; 2006 Jun; 66(11):5858-66. PubMed ID: 16740725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors.
    Griffin JM; Amand MS; Demetri GD
    Clin J Oncol Nurs; 2005 Apr; 9(2):161-9. PubMed ID: 15853160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Imatinib in the GIST therapy: ten years later].
    Lopez M
    Clin Ter; 2011; 162(6):563-73. PubMed ID: 22262331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
    Liegl B; Hornick JL; Antonescu CR; Corless CL; Fletcher CD
    Am J Surg Pathol; 2009 Feb; 33(2):218-26. PubMed ID: 18830121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.
    Bauer S; Duensing A; Demetri GD; Fletcher JA
    Oncogene; 2007 Nov; 26(54):7560-8. PubMed ID: 17546049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment progress of gastrointestinal stromal tumor].
    Ji X; Ji JF
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):292-6. PubMed ID: 23536354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.